S

Sanofi

Global pharma company; vaccines and R&D

CMC Synthetics Platform Process and Pharmaceutical Engineering Scientist

Spring 2027Updated on 10/1/2026Deadline 10/23/26
$45 - $57/hr
Internship
Master's, PhD
Cambridge, MA, USA
In PersonMust relocate to the Cambridge office and work 40 hours per week, Monday through Friday, for the full co-op.
No H1B Sponsorship

About the job

Requirements
  • Currently pursuing a Master's or PhD degree in Chemical Engineering, Mechanical Engineering, Materials Science, Pharmaceutical Engineering, Biomedical Engineering, or a related technical field.
  • Must be permanently authorized to work in the United States and not require employment visa sponsorship, including H-1B or green card sponsorship, at the time of application or in the future.
  • Must remain enrolled at an accredited college or university throughout the duration of the co-op.
  • Must be able to relocate to the office location and work 40 hours per week, Monday through Friday, for the full duration of the co-op.
  • Strong interest in material science, solid mechanics, and pharmaceutical process engineering.
  • Familiarity with data analysis and scientific programming such as Python, MATLAB, R, or similar tools.
  • Autonomy and interest in laboratory experiments.
  • Ability to work collaboratively in a team environment.
  • Excellent communication skills for interacting with scientists and engineers.
Responsibilities
  • Predict and analyze single-crystal material properties relevant to pharmaceutical development, including mechanical behavior, elastic properties, and anisotropy.
  • Evaluate how crystal structure and morphology influence downstream processing and manufacturability.
  • Design and execute experimental studies to characterize tablet mechanical performance, including diametral compression and dynamic breakage testing.
  • Use digital image correlation and related imaging tools to quantify strain localization, crack initiation, and failure mechanisms.
  • Integrate experimental and modeling results to improve mechanistic understanding of material-process-performance relationships.
  • Collaborate with scientists and engineers to translate findings into predictive frameworks that support formulation and process design.
Desired Qualifications
  • Exposure to solid-state chemistry, crystal structure analysis, powder mechanics, or pharmaceutical unit operations.
  • Familiarity with molecular and solid-state modeling tools such as Mercury, Materials Studio, or related crystallographic or molecular simulation software.
  • Experience with computational modeling tools such as finite element methods, Abaqus, COMSOL, or similar tools.
  • Familiarity with experimental mechanics or imaging methods such as digital image correlation.
  • Experience analyzing scientific data and presenting technical results.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi completed Vicebio on December 4, 2025, adding RSV-HMPV vaccine technology.
  • Sanofi completed Dynavax on February 10, 2026, expanding hepatitis B and shingles assets.
  • FDA approved wearable Sarclisa on July 2026, improving multiple myeloma convenience.

What critics are saying

  • Dupixent loses patent exclusivity in 2031, exposing Sanofi’s cash engine.
  • EU regulators opened a June 26, 2026 antitrust probe over Efluelda marketing.
  • Sanofi sued Pfizer and Moderna on July 15, 2026 over COVID-shot patents.

What makes Sanofi unique

  • Dupixent and partner Regeneron still anchor Sanofi’s immunology franchise in 2026.
  • Vicebio’s Molecular Clamp and Dynavax deepen Sanofi’s respiratory and adult vaccine platform.
  • Frankfurt insulin manufacturing, backed by Germany’s 2026 subsidy, protects European supply security.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...